Abstract: The present invention relates to fully human antibodies and conjugates thereof, which specifically bind to the extracellular domain of receptor tyrosine kinase-like orphan receptor 2 (ROR2).

Abstract: The present disclosure relates to methods of re-oxidizing an antigen-binding protein.

Abstract: The present invention provides a composition comprising a first antibody molecule that specifically recognizes CD3 and a second antibody molecule that specifically recognizes CD7, for use in a method of treatment, or preventative treatment of viral infection or viral reactivation in a mammalian subject undergoing immunomodulatory treatment, wherein the first and second antibody molecules are each provided with a toxic moiety. Also provided is a method of treating a mammalian subject having, or being at risk of developing, chronic Graft versus Host disease (cGVHD). Also provided is a related pharmaceutical composition.

Abstract: Described is the sequential administration of first a Treg depleting antibody molecule selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti-body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. Described are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.

Abstract: This disclosure relates to synthetic ligands for detecting PD-L1 in a sample or subject. The ligand can be labeled with a variety of detectable labels allowing of visualization and quantification. The ligand provides an alternative PD-L1 binding molecule with advantages over current antibody technologies for detecting PD-L1.

Abstract: Compositions and methods of making isolated binding molecules (e.g. an antibodies) or antigen-binding fragment thereof useful as therapeutics for treating and/or preventing diseases associated with cells expressing claudin18.2, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder are described. Also, described are pharmaceutical formulations comprising the described compositions for the treatment of diseases either as single agent (e.g., naked antibodies) or as adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1/PD-L1 monoclonal antibodies), and/or by combination therapies where the anti-claudin18.2 antibodies are administered before, after, or concurrently with chemotherapy.

Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.

Abstract: Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.

Abstract: This application provides: an antibody which specifically binds to an ALK2 protein and has an activity of inhibiting BMP signal transduction mediated by ALK2; a method for producing the antibody; and a pharmaceutical composition comprising the antibody, for treating and/or preventing ectopic ossification and/or bone dysplasia, anemia, or diffuse intrinsic pontine glioma (DIPG).

Abstract: The present disclosure relates to methods for treating type 1 diabetes (T1D) using a glucagon receptor blocking agent. More specifically, the present disclosure relates to methods for treating T1D using substantially lower doses of insulin supplementation, or even in the absence of insulin supplementation, using antigen binding and antagonizing proteins, e.g., fully human antibodies that specifically bind to and antagonize the function of the human glucagon receptor.

Abstract: Provided herein are VHH-containing polypeptides that bind OX40. In some embodiments, VHH-containing polypeptides that bind and agonize OX40 are provided. Uses of the VHH-containing polypeptides are also provided.

Abstract: The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.

Abstract: The invention relates to new bispecific antigen binding molecules, comprising at least one antigen binding domain capable of specific binding to 4-1BB, at least one moiety capable of specific binding to a target cell antigen, and a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

Abstract: Provided according to an embodiment of the present invention is an antibody that binds specifically to B-cell maturation antigen (BCMA) and comprises a heavy chain variable domain (VH domain) composed of a sequence having a homology of 80% or higher with any one of the amino acid sequences of SEQ ID NOS: 1 to 20, or a fragment thereof.

Abstract: Methods are provided for the synthesis and secretion of recombinant hetero-multimeric proteins in mating competent yeast. A first expression vector is transformed into a first haploid cell; and a second expression vector is transformed into a second haploid cell. The transformed haploid cells, each individually synthesizing a non-identical polypeptide, are identified and then genetically crossed or fused. The resulting diploid strains are utilized to produce and secrete fully assembled and biologically functional hetero-multimeric protein.

Abstract: The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.

Abstract: A chimeric antigen receptor (CAR) having an antigen binding domain capable of binding to CA215. The antigen binding domain can have a binding affinity and specificity similar to the RP215 antibody. Methods of making and using such CARs are provided. The CARs can be used to treat cancer.

Abstract: Methods are provided for identifying and selecting antibodies that are internalized into cells via the macropinocytosis pathway. Additionally antibodies that are internalized via this pathway are provided as well as immunoconjugates comprising such antibodies.

Abstract: The present application provides constructs comprising an antibody moiety specifically recognizing Glypican 3 (GPC3), such as a cell surface-bound GPC3. Also provided are methods of making and using these constructs.

Abstract: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.

Abstract: Provided herein are antibodies that specifically bind to human tissue factor (TF), anti-TF antibody-drug conjugates (ADCs), and compositions comprising the antibodies or ADCs. Also provided herein are methods of making and using the antibodies or ADCs, such as therapeutic and diagnostic methods.

Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human FLT3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.

Abstract: Compositions and methods for the treatment of an ocular disease or disorder are disclosed.

Abstract: Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0×10?9 or less. Optionally, the anti-PAD4 antibody and a TNF? inhibitor are used in combination.

Abstract: A binding unit that specifically binds to fibroblast activation protein ? (FAP?), a polynucleotide that encodes the binding unit, a vector that comprises the polynucleotide and a host cell, a method for use in producing the antigen-binding unit and a method for treating a disease by using the FAP?-specific binding unit; the binding unit that specifically binds to FAP? may efficiently bind to tumor cells that express FAP?, and immune effector cells comprising the binding unit exhibit significant killing capabilities against tumor cells that express FAP.

Abstract: The present application is directed to anti-lambda myeloma antigen (LMA) binding proteins, wherein the binding protein is an antibody. Compositions comprising these antibodies and nucleic acids encoding these antibodies are also disclosed. These antibodies, compositions and nucleic acids may be used in the treatment of LMA expressing pathologies.

Abstract: Monoclonal antibodies directed to ceramide that inhibit apoptosis are disclosed. Humanized and scFv versions of the antibodies are also disclosed. Methods for prevention or treatment of apoptosis in a subject by administration of the anti-ceramide antibodies are disclosed.

Abstract: Disclosed herein are multispecific, such as bispecific, antigen binding proteins comprising a first antigen binding domain comprising a heavy chain variable domain and a light chain variable domain, and a second antigen binding domain comprising a single-domain antibody. Pharmaceutical compositions comprising the multispecific antigen binding proteins, kits and methods of use thereof are further provided.

Abstract: The monoclonal IgG-type antibodies were suggested comprising variable domains represented by a combination of VHH-derivative with a variable domain of the light chain VL. Said antibodies can comprise amino acid substitutions at positions 44 and 45 (Kabat numbering) or combinations thereof. Antibodies of the invention possess increased affinity and improved aggregation stability.

Abstract: Provided herein is a platform technology for the generation of properly paired bispecific antibodies. Some of the antibodies generated have Fc region modifications, in particular in their CH3 domains by lysine repositioning to drive heterodimerization of the two heavy chains of the bispecific antibody. Some of the antibodies generated have Fab arm modifications to prevent mispairing of light chains. Specifically, the CH1 and CL domains of one of the Fab arms of the bispecific antibody are substituted with an IgE CH2 domain or an IgM CH2 domain.

Abstract: A process for preparing a recycle cellulose ester and a recycle cellulose ester composition and articles made with such recycle cellulose esters comprising at least one cellulose ester having at least one substituent on an anhydroglucose unit (AU) derived from recycled plastic content syngas are provided. The recycled plastic content syngas can be obtained by gasifying feedstocks containing a solid fossil fuel such as coal, a plastic, and water. The plastic can be post-consumer or postindustrial plastic.

Abstract: The present disclosure relates to polymers comprising conjugates of cyclodextrin or derivatives thereof and a linker moiety, methods of preparing the same and their application in the removal of lipids such as cholesterol from cells in treating lipid storage disorders. The present polymers exhibit improved properties including but not limiting to improved biocompatibility, improved retention time, prolonged duration of action in cells, and increased efficacy in removal of cholesterol from cells in treating lipid storage disorders.

Abstract: The present invention relates to [1] a process for producing a water-based pigment dispersion, including step 1 of subjecting an ionic group-containing monomer (a) and a hydrophobic monomer (b) to polymerization reaction using an ionic group-containing polymerization initiator (x) and an ionic group-containing chain transfer agent (y) to obtain an ionic group-containing polymer A, step 2 of mixing and dispersing the obtained polymer A and a pigment in an aqueous medium to obtain a pigment water dispersion, and step 3 of subjecting the polymer A in the obtained pigment water dispersion to crosslinking reaction with a polyfunctional compound to obtain the water-based pigment dispersion, and [2] a process for producing a water-based ink, including, in addition to the aforementioned steps 1 to 3, step 4 of mixing the obtained water-based pigment dispersion with an organic solvent to obtain the water-based ink.

Abstract: The present invention relates to a process for preparing a poly(meth)acrylic acid, characterized in that a (meth)acrylic acid-containing process stream from (meth)acrolein synthesis is subjected to free-radical polymerization. The invention also relates to the esterification of the polymer obtained to give a homopolymer or copolymer ester, and to the use thereof as additive, flow improver and water reducer.

Abstract: This invention relates to a solid MgCb-based Natta catalyst component comprising a C2 to C6 alkyl tetrahydrofurfuryl ether as internal electron donor for producing olefin polymers and preparation of said catalyst component. Further, the invention relates to a Ziegler-Natta catalyst comprising said solid catalyst component, Group 13 metal compound as co-catalyst and optionally external additives. The invention further relates to the use of said catalyst component in producing olefin polymers, especially ethylene copolymers.

Abstract: The invention relates to a method for selective hydrogenation. More specifically, it relates to a method for selective hydrogenation capable of improving selectivity and reaction efficiency in the hydrogenation process of petroleum resin.

Abstract: Some embodiments described herein relate to new polymer coatings for surface functionalization and new processes for grafting pre-grafted DNA-copolymers to surface(s) of substrates for use in DNA sequencing and other diagnostic applications.

Abstract: The invention is generally related to a process for producing a relatively high molecular weight poly(methacrylic acid) (“PMAA”) in a water-based system. The process of the invention comprises polymerization of from about 1% to about 20% by weight of methacrylic acid in water or a water-based system in the presence of thiol compound and an azo radical initiator under controlled reaction and process conditions. A process of the invention can be easily scaled up into the pilot scale for producing large quantities of high molecular weight PMAAs. The invention is also related to high molecular weight poly(methacrylic acid)s obtained according to a process of the invention.

Abstract: Embodiments of this disclosure include processes of polymerizing olefins, the process comprising contacting ethylene and a (C3-C40)alpha-olefin comonomer in the presence of a catalyst system, the catalyst system comprising a Group IV metal-ligand complex and a metallic activator ionic complex, the metallic activator ionic complex comprising an anion and a countercation, the anion having a structure according to formula (I):

Abstract: The present invention relates to a process for the manufacture of a functionalized ethylene and propylene copolymer composition. The invention further relates to such functionalized ethylene and propylene copolymer composition.

Abstract: Embodiments of this disclosure include processes of polymerizing olefins, the process comprising contacting ethylene and a (C3-C40)alpha-olefin comonomer in the presence of a catalyst system, the catalyst system comprising a Group IV metal-ligand complex and an ionic metallic activator complex, the ionic metallic activator complex comprising an anion and a countercation, the anion having a structure according to formula (I):formula (I)

Abstract: Methods for scale-up from a pilot plant to a larger production facility of a bimodal polymer product having a density, a melt index and melt index ratio are provided herein.

Abstract: The invention relates to the field of preparing aqueous dispersions of organic, organometallic or inorganic particles. In particular, the invention relates to the preparation of aqueous suspensions comprising organic, organometallic or inorganic particles and at least one particular copolymer obtained by polymerization of at least one acid and at least one compound or at least one ester derived from a particular acid, in the presence of water, at least one initiator compound and at least one activator compound, followed by total or partial neutralization by means of at least one compound chosen from alkali metal hydroxides, alkaline earth metal hydroxides, alkaline earth metal dihydroxides and mixtures thereof. The invention relates to such a particular copolymer having a low polydispersity index and weight-average molecular weight, the preparation process thereof and the use thereof, especially for the preparation of an aqueous paint composition.

Abstract: A main chain of a temperature-resistant and anti-collapse multi-branched polymer fluid loss reducer is composed of the following repeating unit (I): In the repeating unit (I): x:y:z=(20˜80):(20˜80):(2˜30); the R1 and R2 groups are alkylamines having a multi-branched structure. The beneficial effect of the multi-branched polymer fluid loss reducer is: introducing cheap acrylamide branch monomer into the polymer monomer system of acrylamide and 2-acrylamido-2-methylpropanesulfonic acid, the preparation process is simple, the reaction conditions are mild, and the production cost is significantly reduced.

Abstract: Disclosed herein is an aqueous latex composition comprising a substantially acrylic core-shell latex, wherein a water-retaining monomer is copolymerized to the shell. The Tg of the core ranges from about 0° C. to about 12° C., and the Tg of the shell ranges from about 13° C. to about 40° C. The mean volume average particle size of the latex ranges from about 125 nm to about 200 nm. The core-shell latex comprises at least one acrylic monomer having a solubility that ranges about 10 g/L to about 30 g/L at 30° C., and this at least one acrylic monomer is present in the shell polymer in an amount greater than about 50 wt. % of all monomers in the shell. Preferably, the at least one acrylic monomer is methyl methacrylate.

Abstract: The invention relates to a piston system (1) for use in a homogenizer, comprising a piston (2) that is configured and arranged to make a reciprocating movement in use of the piston system, a cylinder (3) that is configured and arranged to receive and guide at least a first part of the piston, a first supply channel (8) that is configured and arranged to supply a lubricating medium (9) to a portion (10) of the first part of the piston that in use is arranged inside the cylinder, and a second supply channel (13) that is configured and arranged to, in use, supply a cooling medium (14) to a second part of the piston outside the cylinder. Also disclosed is a process for the production of an elastomer agglomerate composition forcing a slurry comprising elastomeric particles through an aperture to obtain the elastomer agglomerate composition using the piston system.

Abstract: Provided herein are block copolymers comprising a hydrophilic polymer segment and a hydrophobic polymer segment, wherein the hydrophilic polymer segment comprises a polymer selected from the group consisting of: poly(ethylene oxide) (PEO), poly(methacrylate phosphatidyl choline) (MPC), and polyvinylpyrrolidone (PVP), wherein the hydrophobic polymer segment comprises wherein R? is —H or —CH3, wherein R is —NR1R2, wherein R1 and R2 are alkyl groups, wherein R1 and R2 are the same or different, wherein R1 and R2 together have from 5 to 16 carbons, wherein R1 and R2 may optionally join to form a ring, wherein n is 1 to about 10, and wherein x is about 20 to about 200 in total. Also provided are pH-sensitive micelle compositions for therapeutic and diagnostic applications.

Abstract: The present invention relates to a process for producing translucent polyurethane and polyisocyanurate foams by reaction of a component A comprising A1 at least one polyol reactive with the component B; A2 optionally at least one amine; A3 water and optionally formic acid; A4 at least one foam stabilizer; A5 optionally auxiliary and/or additive substances; A6 optionally at least one flame retardant; A7 at least one catalyst; and a component B comprising B1 at least one aliphatic or cycloaliphatic polyisocyanate component or a combination thereof; and B2 optionally at least one hydrophilized isocyanate; and B3 less than 20 parts by weight of an aromatic polyisocyanate component, wherein the parts by weight of B3 are based on the sum of the parts by weight of B1 to B3 normalized to 100 parts by weight, characterized in that the reaction of the component A with the component B is carried out at an isocyanate index of at least 150, wherein the obtained translucent polyurethane and polyisocyanurate foams have a li

Abstract: Pultrudate based on polyurethane and carbon fibers and the production and use thereof.

Abstract: The present invention relates to a thermoplastic polyurethane obtainable or obtained by reacting a polyisocyanate composition, a chain extender, and a polyol composition, wherein the polyol composition comprises a polyol (P1) which has a molecular weight Mw in the range from 1500 to 2500 g/mol and has at least one aromatic polyester block (B1). The present invention further relates to a process for producing a shaped body comprising such a thermoplastic polyurethane, and to shaped bodies obtainable or obtained by a process of the invention.